| CENTER ID: | BupsA.00010.b |
| ORGANISM: | Burkholderia pseudomallei 1710b |
| ASSOCIATED DISEASE: | Melioidosis |
| CURRENT STATUS: | in PDB |
| COMMUNITY REQUEST: | True |
| NIH RISK GROUP: | 3 |
| SELECT AGENT: | True |
| NIH PRIORITY pathogens category: |
IIIB |
| CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
|---|---|---|---|---|---|
| BupsA.00010.b.B1.PS00034 | Full length( BupsA.00010.b ) | 1 | 263 |
| Rational Optimization of Diphenyl Ether Binding Kinetics to the Enoyl-ACP Reductase FabI1 from Burkholderia pseudomallei | |
| C Neckles, S Eltschkner, JE Cummings- Biochemistry, 2017 - ncbi.nlm.nih.gov | |
| cited by: | 1 other |
| PDB: 3EK2 | |
| Crystalline Structure of FABI from Burkholderia Pseudomallei | |
| NR Krishnamurthy - US Patent , 2017 - freepatentsonline.com | |
| PDB: 3EK2 |
| Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase | |
| C Neckles, S Eltschkner, JE Cummings - Biochemistry, 2017 - ACS Publications | |
| PDB: 3EK2 |
| Pyridone FabI Inhibitors and Uses Thereof | |
| P Tonge - US Patent App. 15/130,365, 2016 - Google Patents | |
| PDB: 3EK2 |
| Rare Sidechain Conformations in Proteins and DNA | |
| BJ Hintze - 2015 - search.proquest.com | |
| PDB: 3EK2 |
| AFN‐1252 is a potent inhibitor of Enoyl‐ACP reductase from Burkholderia pseudomallei‐Crystal structure, Mode of action and biological activity | |
| KN Rao, A Lakshminarasimhan, S Joseph… - Protein …, 2015 - Wiley Online Library | |
| PDB: 3EK2 |
| Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor | |
| J Schiebel, A Chang, S Shah, Y Lu, L Liu, P Pan - Journal of Biological Chemistry, 2014 - ASBMB | |
| cited by: | 13 others |
| PDB: 3EK2 | |
| Paclitaxel Induces Apoptosis in Breast Cancer Cells through Different Calcium-Regulating Mechanisms Depending on External Calcium Conditions | |
| Z Pan, A Avila, L Gollahon - International journal of molecular sciences, 2014 - mdpi.com | |
| PDB: 3EK2 |
| < i> Staphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo Essentiality | |
| J Schiebel, A Chang, H Lu, MV Baxter, PJ Tonge? - Structure, 2012 - Elsevier | |
| cited by: | 33 others |
| PDB: 3EK2 | |
| High-resolution structures of Thermus thermophilus enoyl-acyl carrier protein reductase in the apo form, in complex with NAD+ and in complex with NAD+ and triclosan | |
| JM Otero, AJ Noel, P Guardado-Calvo? - Acta Crystallographica Section F Structural Biology and Crystallization Communications, 2012 - scripts.iucr.org | |
| cited by: | 2 others |
| PDB: 3EK2 | |
| Structure-based drug design on the enoyl-ACP reductases of Yersinia pestis and Burkholderia pseudomallei | |
| MW Hirschbeck - opus.uni-wuerzburg.de | |
| PDB: 3EK2 |
| Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan | |
| A Priyadarshi, EEK Kim? - Proteins: Structure, Function, and Bioinformatics, 2010 - Wiley Online Library | |
| cited by: | 23 others |
| PDB: 3EK2 | |
| RESOURCE | REFERENCE ID |
|---|---|
| BV-BRC: | fig|320372.6.peg.2759 |
| RefSeq: | YP_334023 |
| UniProt: | Q3JQY0 |
| PURIFICATION DATe: | 7/1/2008 |
| CONCENTRATION: | 25.05mg/ml |
| OBSERVED MW: | data unavailable |
| EXPRESSION LEVEL: | High Expression |
| PROTEIN PURIFICATION BUFFER: | 20 mM HEPES, pH 7.0, 300 mM NaCl, 5% glycerol and 1 mM TCEP |
| EXPRESSION HOST: | data unavailable |
| VIAL COUNT (approx.): | 22 |
| VIAL VOLUME: | 100µl |
| PERCENT IDENTITY: | 100 |
| PERCENT COVERAGE: | 100 |